Skye Bioscience, Inc.

Skye Bioscience, Inc. has raised $152.2M in total funding. The most recent round was Series B.

Skye Bioscience, Inc. is headquartered in San Diego, CA.

We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.

Current anti-obesity therapeutics still lack differentiated mechanisms to deliver persistent weight loss, improved body composition, and better drug tolerability.

Skye Bioscience develops next-generation drugs that modulate G-protein coupled receptors, led by nimacimab, a peripheral CB1 receptor inhibitor intended to complement existing anti-obesity treatments like GLP-1 drugs.

Nimacimab is a potentially first-in-class peripheral CB1-inhibiting antibody with limited CNS accumulation in studies to date, a positive Phase 1 safety profile with no neuropsychiatric adverse events, and Phase 2a data showing added weight loss when combined with semaglutide without increased GI issues.

Skye Bioscience is led by CEO Punit Dhillon, who previously co-founded and served as CEO of OncoSec Medical, a cancer immunotherapy developer.